Palisade Bio, Inc. announced on July 24, 2025, an agreement with several accredited investors for the exercise of existing warrants to purchase up to 4,318,905 shares of common stock. This transaction is expected to generate approximately $3.9 million in gross proceeds for the company.
The existing warrants, which had adjusted exercise prices of $1.40, were exercised at a reduced price of $0.9047 per share. In consideration for this immediate cash exercise, the holders will receive new unregistered warrants to purchase up to 8,637,810 shares of common stock at an exercise price of $0.9047 per share.
The company intends to use the net proceeds from this transaction for working capital and general corporate purposes. While providing necessary capital, the reduced exercise price and issuance of new warrants indicate further dilution for current shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.